VIR_logo_large_color.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
October 11, 2023 08:00 ET | Vir Biotechnology, Inc.
Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.
VIR_logo_large.jpg
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
May 11, 2023 08:30 ET | Vir Biotechnology, Inc.
– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
July 21, 2022 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
VIR_logo_large.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
June 08, 2022 07:34 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been...
VIR_logo_large.jpg
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
May 18, 2022 16:03 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:07 ET | Vir Biotechnology, Inc.
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the...
VIR_logo_large.jpg
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
April 13, 2022 16:02 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment...
VIR_logo_large.jpg
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
June 25, 2021 08:50 ET | Vir Biotechnology, Inc.
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents – – Management to host conference...
VIR_logo_large.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021
June 14, 2021 08:00 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, June 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted...